RDUS Radius Health Inc.

Radius Health to Present at the 39th Annual J.P. Morgan Healthcare Conference

Radius Health to Present at the 39th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Kelly Martin, President and CEO will present a virtual corporate update at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13 at 9:10 a.m. EST.

A live webcast of the presentation will be available by visiting the Investors section of Radius’ website at . A replay of the webcast will be archived on Radius’ website for 90 days following the presentation.

About Radius

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes the investigational use of abaloparatide injection for the treatment of men with osteoporosis, an investigational abaloparatide-patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer out-licensed to Menarini Group. For more information, please visit  

Investor & Media Relations Contact:

Peter Schwartzman

Email: 

Phone: (617) 583-2017



EN
06/01/2021

Underlying

RDUSRadius Health Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Radius Health Inc.

 PRESS RELEASE
Free
RDUS Radius Health ...

Gurnet Point Capital and Patient Square Capital Complete Their Acquisi...

Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc. CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (“Radius”). Radius is a global, commercial-stage biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and neuro-orphan diseases. Radius’ lead product, TYMLOS® (abaloparatide) was launched in the U.S. in 2017 for the treatment of...

August 15, 2022 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 46.63
XNCR XENCOR INC.
VCYT VERACYTE INC ... (+33)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

XNCR XENCOR INC.
VCYT VERACYTE INC
RDUS RADIUS HEALTH INC.
FOLD AMICUS THERAPEUTICS INC.
CYTK CYTOKINETICS INCORPORATED
AVXL ANAVEX LIFE SCIENCES
AGIO AGIOS PHARMACEUTICALS INC.
NTLA INTELLIA THERAPEUTICS INC.
CYRX CRYOPORT INC.
DH DELICE HOLDING
FNKO FUNKO CLASS A
RCKT ROCKET PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
ALEC ALECTOR
RAD RITE AID CORPORATION
TMDX TRANSMEDICS GROUP
CHWY CHEWY INC. CLASS A
HCAT HEALTH CATALYST
RAPT RAPT THERAPEUTICS
ALT ALTIMMUNE INC
AVEO AVEO PHARMACEUTICALS INC.
SPT SPROUT SOCIAL
FSTX F-STAR THERAPEUTICS INC
MASS 908 DEVICES
DAWN DAY ONE BIOPHARMACEUTICALS INC
GTLB GITLAB INC
AGL AGILON HEALTH INC
VERV VERVE THERAPEUTICS INC
GLUE MONTE ROSA THERAPEUTICS INC
BRZE BRAZE INC
RXRX RECURSION PHARMACEUTICALS INC
JANX JANUX THERAPEUTICS INC
WEBR WEBER INC
06/24/22 June 24, 2022 1 EN
 PRESS RELEASE
Free
RDUS Radius Health ...

Radius Health Announces Agreement to be Acquired by Gurnet Point Capit...

Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital Transaction delivers immediate value and liquidity to Radius shareholdersResult of nine-month strategic review process by the Radius Board to maximize shareholder valuePotential per share value of $11.00, including $10.00 cash paid at closing and potential $1.00 CVRRepresents total transaction consideration of up to approximately $890 million BOSTON and CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced tha...

June 23, 2022 1 EN
 PRESS RELEASE
Free
RDUS Radius Health ...

Menarini Group and Radius Health Submit New Drug Application to the U....

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patientsPriority Review requested; if accepted, anticipate an 8-month FDA reviewPositive EMERALD study data previously announced on October 20, 2021First, and currently only, investigational oral SERD with positive topline resultsAdditional data presented at SABCS (December 2021) and ASCO (June 2022)Plan to file marketing authorization application for elacestrant in the EU in 2H 2022 FLORENCE, Italy and BOSTON, June ...

June 22, 2022 1 EN
 PRESS RELEASE
Free
RDUS Radius Health ...

Radius Health Expands Non-US Market Footprint for TYMLOS

Radius Health Expands Non-US Market Footprint for TYMLOS Globalization has been a key priority for the Company over the past two yearsThree additional market agreements now signed and executed:- Labatec Pharma SA: Switzerland, Middle East & North Africa (MENA) countries- Pharmbio Korea Inc.: South Korea- Biosidus: Colombia, South AmericaEconomics: upfront payments, regulatory & commercial milestones, and COGS marginAdds 13 new countries to the current non-US countries of Japan and CanadaJapan: regulatory approval of 14-day cartridge anticipated in 2H 2022 followed by launchCanada: regulator...

June 8, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch